Hakim Anat, an executive vice president and general counsel at Eli Lilly & Co, has reported a transaction involving the sale of 5,000 shares of the company's common stock. The sale occurred on November 2, 2026, and is part of a trading plan established under Rule 10b5-1, which allows executives to sell shares at predetermined times to avoid allegations of insider trading. This transaction highlights the ongoing trading activities of company executives and their financial strategies.

Background

Eli Lilly & Co is a prominent player in the pharmaceutical preparations industry, known for its innovative products and commitment to improving patient outcomes. The company is headquartered in Indianapolis, Indiana, and operates under the Central Index Key (CIK) 0000059478. Recent filings indicate a consistent pattern of transactions by its executives, reflecting the dynamic nature of the market.

What the Filing Says

According to the filing dated November 3, 2026, Hakim Anat sold 5,000 shares at a price of $1,402.52 per share. Following this transaction, Anat now holds 4,137.456 shares directly. The filing notes that the transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 10, 2026. Additionally, it mentions that Anat disclaims beneficial ownership of certain reported securities except to the extent of her pecuniary interest.

Impact

This transaction may affect various stakeholders, including investors and analysts monitoring Eli Lilly's executive activities. As a key executive, Anat's trades can influence perceptions of the company's stability and future performance. The pharmaceutical preparations sector continues to experience fluctuations, making such disclosures relevant for market participants.

What's Next

The filing does not say what happens next.